ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9724
0.00%
Brent Oil
82.765
0.00%
Bitcoin
63,669.88
-0.35%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Aurinia Pharmaceuticals Inc (AUPH)

  7. Aurinia Pharmaceuticals Inc (AUPH) Noticias

AUPH

Aurinia Pharmaceuticals (AUPH)

Aurinia Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:AUPH
FechaHoraFuenteTítuloSímboloCompañía
02/05/202405:00Business WireAurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational ResultsNASDAQ:AUPHAurinia Pharmaceuticals Inc
01/05/202405:00Business WireAurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness MonthNASDAQ:AUPHAurinia Pharmaceuticals Inc
30/04/202405:00Business WireThe U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical ProgramNASDAQ:AUPHAurinia Pharmaceuticals Inc
16/04/202409:48Business WireUPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceNASDAQ:AUPHAurinia Pharmaceuticals Inc
15/04/202405:00Business WireAurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024NASDAQ:AUPHAurinia Pharmaceuticals Inc
09/04/202405:00Business WireAurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor ConferenceNASDAQ:AUPHAurinia Pharmaceuticals Inc
07/03/202415:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AUPHAurinia Pharmaceuticals Inc
29/02/202415:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUPHAurinia Pharmaceuticals Inc
29/02/202407:30Business WireAurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase ProgramNASDAQ:AUPHAurinia Pharmaceuticals Inc
27/02/202407:30Business WireAurinia to Participate in Upcoming Investor Healthcare ConferencesNASDAQ:AUPHAurinia Pharmaceuticals Inc
22/02/202415:19Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:AUPHAurinia Pharmaceuticals Inc
15/02/202405:16Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AUPHAurinia Pharmaceuticals Inc
15/02/202405:00Business WireAurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder ValueNASDAQ:AUPHAurinia Pharmaceuticals Inc
14/02/202414:27Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:AUPHAurinia Pharmaceuticals Inc
05/02/202407:30Business WireAurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024NASDAQ:AUPHAurinia Pharmaceuticals Inc
05/01/202405:00Business WireAurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue ResultsNASDAQ:AUPHAurinia Pharmaceuticals Inc
20/12/202305:00Business WireAurinia Submits IND Application to US Food & Drug Administration for AUR 200NASDAQ:AUPHAurinia Pharmaceuticals Inc
13/11/202305:00Business WireAurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in JapanNASDAQ:AUPHAurinia Pharmaceuticals Inc
07/11/202309:30Business WireAurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023NASDAQ:AUPHAurinia Pharmaceuticals Inc
02/11/202317:00Business WireAurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus NephritisNASDAQ:AUPHAurinia Pharmaceuticals Inc
02/11/202305:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AUPHAurinia Pharmaceuticals Inc
02/11/202305:00Business WireAurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational ResultsNASDAQ:AUPHAurinia Pharmaceuticals Inc
26/10/202314:00Business WireAurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus NephritisNASDAQ:AUPHAurinia Pharmaceuticals Inc
19/10/202309:31Business WireCORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023NASDAQ:AUPHAurinia Pharmaceuticals Inc
19/10/202305:00Business WireAurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023NASDAQ:AUPHAurinia Pharmaceuticals Inc
13/10/202311:00Business WireAurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR)NASDAQ:AUPHAurinia Pharmaceuticals Inc
22/09/202315:31Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AUPHAurinia Pharmaceuticals Inc
21/09/202305:00Business WireAurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT CapitalNASDAQ:AUPHAurinia Pharmaceuticals Inc
21/08/202305:00Business WireAurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic PipelinesNASDAQ:AUPHAurinia Pharmaceuticals Inc
03/08/202305:00Business WireAurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational ResultsNASDAQ:AUPHAurinia Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:AUPH

Su Consulta Reciente

USI
USTECH100
US Tech 100
NASDAQ
AMZN
Amazon.com
NYSE
VZ
Verizon Communications
NYSE
JPM
JP Morgan Chase
CCOM
OILBRENT
Brent Oil
USOTC
BNPQY
BNP Paribas (QX)
USOTC
BASFY
BASF (QX)
SPI
SP500
S&P 500
AMEX
XLV
Health Care Select Sector
AMEX
XLF
Financial Select Sector
NYSE
CVX
Chevron
COIN
ETHUSD
Ethereum
NASDAQ
TSLA
Tesla
USOTC
RHHBY
Roche (QX)
NASDAQ
NVDA
NVIDIA
NASDAQ
MSFT
Microsoft
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados